Media Articles Related to Relenza (Zanamivir)
Improved understanding of influenza evolution
Source: Flu / Cold / SARS News From Medical News Today [2014.02.28]
Researchers at Columbia University and the University of Cologne have created a new model to successfully predict the evolution of the influenza virus from one year to the next. This advance in our understanding of influenza suggests a new, systematic way to select influenza vaccine strains. The findings appear in the journal Nature.The flu is one of the major infectious diseases in humans.
Researchers discover immune signature that predicts poor outcome in influenza patients
Source: Flu / Cold / SARS News From Medical News Today [2014.02.13]
A study led by St. Jude Children's Research Hospital identifies factors that predict flu severity in patients and sets the stage for more effective therapies to prevent flu complications and deathsSt.
Potential treatment found for drug-resistant H7N9 influenza virus
Source: Bird Flu / Avian Flu News From Medical News Today [2014.01.20]
The novel avian H7N9 influenza virus has caused more than 130 human infections with 43 deaths in China. New research, conducted under the supervision of Kansas State University's Juergen Richt, is showing promise in helping to fight this deadly virus.
Some indigenous groups more susceptible to the effects of the new strain of influenza in China
Source: Bird Flu / Avian Flu News From Medical News Today [2014.01.15]
Research indicated that some Indigenous people such as in Alaska and Australia displayed limited immunity response to the effects of influenza.
Preparing against Tamiflu-resistant influenza viruses
Source: Bird Flu / Avian Flu News From Medical News Today [2013.12.11]
Researchers in Umea and Uppsala have found that residues of the influenza drug Tamiflu in our environment can make the influenza virus in birds resistant. This can have serious consequences in the event of an influenza pandemic.
Published Studies Related to Relenza (Zanamivir)
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. [2010.11.02]
CONCLUSIONS: In adults with seasonal influenza A mainly H3N2 virus infection, the oseltamivir-zanamivir combination appeared less effective than oseltamivir monotherapy, and not significantly more effective than zanamivir monotherapy. Despite the theoretical potential for the reduction of the emergence of antiviral resistance, the lower effectiveness of this combination calls for caution in its use in clinical practice. TRIAL REGISTRATION: www.ClinicalTrials.govNCT00799760.
A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. [2008.01]
OBJECTIVE: To compare the effectiveness of zanamivir with oseltamivir for influenza A and B... CONCLUSION: Zanamivir therapy is more effective than oseltamivir for the treatment of influenza B infection.
Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. [2007.08]
Background: Influenza can cause significant morbidity and mortality in subjects at high risk for complications, including the elderly (age >/=65 years) and those with chronic respiratory, cardiovascular, or metabolic conditions...
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. [2003.06]
Influenza is an important cause of hospitalization due to lower respiratory tract involvement for which there is no specific antiviral treatment with proven efficacy. We conducted a double-blind, randomized, placebo-controlled trial to assess the tolerability and efficacy of nebulized zanamivir (16 mg four times a day) in combination with rimantadine compared to rimantadine with nebulized saline for treating influenza in adults hospitalized with influenza...
Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. 
A randomized, double-blind, placebo-controlled, parallel-group trial performed at 5 residential units of the Finnish Defence Forces was conducted to assess the antiviral activity, efficacy and safety of inhaled zanamivir for the treatment of naturally acquired influenza... Zanamivir rapidly reduced viral load following the start of therapy compared with placebo and was well tolerated.
Clinical Trials Related to Relenza (Zanamivir)
Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital [Recruiting]
The purpose of this study is to determine whether zanamivir aqueous solution given by
intravenous injection is safe in treating hospitalized patients with confirmed influenza
infection. A single arm open-label design has been selected to achieve the primary
objective of providing regulatory authorities with safety data on IV zanamivir.
Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir [Not yet recruiting]
In order to prevent the high mortality due to an hypothetic pandemic caused by a newly
emerging influenza A virus, antiviral drugs are seen as essential requirements for control of
initial influenza outbreaks. Two antivirals are available for the treatment oseltamivir and
zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared
opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will
be investigated by a randomized, placebo controlled, double blind study in France, during the
next winter season . This study will be conducted in 300 centres of primary care with 900
adults with a virologically suspected influenza A infection. Individuals will be randomized
to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo
+zanamivir. The primary judgment criteria will be the proportion of patients with negative RT
PCR negative in nasal secretions at Day 2.
A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects [Terminated]
This study is a 4 period study to see if there is any interaction between Orally-Administered
Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults [Recruiting]
Due in part to widespread availability of oseltamivir and clinical experience using
oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become
resistant to it. Other reliable methods of treating H5N1 must be identified in case of a
pandemic. One such option is intravenous zanamivir used in combination with oseltamivir. The
primary purpose of this study is to evaluate the interaction between oral oseltamivir and
intravenous zanamivir administered as either a continuous or intermittent infusion in
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection [Recruiting]
The outbreak of respiratory illnesses in Mexico that began in March 2009 was caused by a
swine origin influenza A (H1N1) virus (S-OIV) that had not been recognized previously in
pigs or humans. As of 17 May 2009, 39 countries have officially reported 8480 cases of
influenza A (H1N1) infection.
The H1N1 influenza A virus appears sensitive to oseltamivir and zanamivir in vitro, but
resistant to amantadine and rimantadine. This study is to test the oseltamivir, zanamivir
and placebo arms as the first line treatment for human swine influenza infection. Through
the study, the investigators may have better understanding about the clinical and,
biochemical, virological profiles of oseltamivir/zanamivir on the H1N1 virus, and optimizing
the treatment strategy among the Chinese population.
Reports of Suspected Relenza (Zanamivir) Side Effects
Abnormal Behaviour (40),
Loss of Consciousness (8),
Depressed Level of Consciousness (8),
Pyrexia (7), more >>